A New Psilocybin Trial Won't Save Anyone This Year — Contingency Management Already Could

Carilion Clinic in Roanoke announced this week that it landed a National Institute on Drug Abuse grant, more than $600,000 with a path to $3.5 million, to test whether a psychedelic compound found in certain mushrooms — psilocybin — paired with structured therapy sessions can reduce cocaine use. Dr. Albert Arias, the clinic’s chief of psychiatry, says Carilion will be one of maybe two or three sites in the country running a trial like this. That’s real, federally funded work, and it deserves attention.

It’s also, realistically, years from touching a patient who isn’t enrolled in a research protocol.

A new psilocybin trial won’t save anyone this year. The treatment already proven to cut mortality is still being rationed by habit.

Here’s the treatment sitting unused while everyone waits on the trial results: pay someone, usually in gift cards, every time they turn in a drug-negative urine sample or show up for a scheduled visit. Clinically it’s called contingency management, and it sounds too simple to count as medicine. It is medicine — arguably the best medicine cocaine treatment has. There’s no pill or injection approved by the FDA for cocaine use disorder, nothing like methadone or buprenorphine for opioids, so a structured incentive schedule isn’t a consolation prize while we wait for a “real” drug. It’s the frontline option. A 2025 cohort study in the American Journal of Psychiatry tracked nearly 3,000 veterans with stimulant use disorder and found that those who received contingency management were 41% less likely to die within a year than those who didn’t. Twenty-seven deaths in the treatment group, forty-six in the comparison group. That’s not a modest effect size. That’s a treatment with a body count attached to withholding it.

So why isn’t every program running it well? Mostly because of an outdated number nobody updated. Federal fraud rules kept incentive payments capped at $75 per patient per year for over a decade — too small to change anyone’s behavior, and everyone in this field knew it. SAMHSA raised that ceiling to $750 per patient per year in January 2025. Most programs still haven’t moved off the old figure. That’s not a funding problem. That’s a program running last decade’s rulebook because nobody checked whether the rules changed.

If you run or work in a treatment program, ask this at your next team meeting: are we issuing incentives up to the new $750 cap, or are we still capping at $75 out of habit? If it’s the old number, you’re delivering a watered-down version of a treatment with a documented mortality benefit, and that gap closes by Friday, not by a grant cycle.

Roanoke’s trial might matter in five years. The veteran who didn’t die this year because someone handed him a gift card for a clean test mattered last week.